
-
Voyager Therapeutics NasdaqGS:VYGR Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Location: 75 Hayden Avenue, Lexington, MA, 02421, United States | Website: https://www.voyagertherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-37.97M
Cash
236M
Avg Qtr Burn
-27.99M
Short % of Float
6.24%
Insider Ownership
16.59%
Institutional Own.
63.52%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AAV Capsids (Pfizer) Details Neurological disorder | Phase 1 Update | |
AAV Capsids (Novartis) Details Cardiovascular disease , Neurological disorder | Phase 1 Initiation | |
AAV Capsids Details Cardiovascular disease , Neurological disorder | Phase 1 Initiation | |
AAV Capsids + ZF-TRs (Sangamo) Details Prion disease | Phase 1 Initiation | |
VY7523 (formerly VT- TAU01) [anti-tau antibody] Details Alzheimer's disease | Phase 1a Data readout | |
GBA1 gene therapy program Details Parkinson's disease, Central nervous system illness | IND Submission | |
VY-AADC (NBIb-1817) Details Parkinson's disease, Central nervous system illness | Failed Discontinued | |
VY9323 (SOD1 silencing gene therapy) Details Neurodegenerative disease, Amyotrophic lateral sclerosis | Failed Discontinued | |
VY-HTT01 Details Huntington's disease | Failed Discontinued |